ImmunityBio's ANKTIVA Shows 96% Survival Rate, FDA Meeting Advances Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: Businesswire
ImmunityBio Inc. saw its stock price surge by 17.39% in pre-market trading, reaching a 52-week high, following significant clinical data presented during an FDA meeting.
The company highlighted a 96% disease-specific survival rate at 36 months for ANKTIVA combined with BCG in treating BCG-unresponsive non-muscle invasive bladder cancer. The FDA has recommended that ImmunityBio submit additional information within the next 30 days to support the resubmission of its supplemental Biologics License Application (sBLA), reflecting the regulatory body's interest and the potential for approval. This progress indicates a strong market position for ANKTIVA, especially as it has already received approvals in multiple regions.
The implications of this development are substantial, as it not only reinforces ImmunityBio's commitment to expanding patient access globally but also positions ANKTIVA as a leading treatment option in a competitive market. The anticipated FDA approval could further enhance the company's growth trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's ANKTIVA Therapy Economic Analysis Reveals Significant Cost Savings
- Significant Cost Savings: ImmunityBio's analysis indicates that ANKTIVA plus BCG can save up to $151,438 per cystectomy avoided in a U.S. Medicare population, highlighting the therapy's potential to reduce healthcare expenditures.
- Comparative Efficacy Advantage: The complete response rate for ANKTIVA plus BCG stands at 49.6%, surpassing TAR-200's 45.9%, while also incurring lower treatment and administration costs, showcasing ANKTIVA's competitive edge in treating BCG-unresponsive NMIBC patients.
- Economic Model Support: The findings are derived from a cost-consequence model utilizing data from ImmunityBio's QUILT-3.032 study and TAR-200's SunRISe-1 trial, emphasizing the potential of ANKTIVA plus BCG to deliver durable responses while lowering costs to the healthcare system.
- Optimistic Investor Sentiment: ImmunityBio's stock has surged 291% year-to-date and 192% over the past 12 months, reflecting a positive investor reaction to the economic analysis results and indicating strong market confidence in the company's future growth.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased securities between January 19 and March 24, 2026, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, leading to materially false and misleading statements about the company's business and prospects, which could result in significant losses for investors.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, demonstrating the legal team's commitment to protecting investor rights.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only if they successfully recover funds, highlighting the firm's strong focus on investor interests and accountability.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that executives made false statements during the class period, resulting in investor losses once the true information was revealed, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and secured over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success rather than those acting merely as intermediaries, ensuring they receive the best representation and support in litigation.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Lawsuit Context: The class action lawsuit seeks to represent investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws, with Hagens Berman investigating claims and urging affected investors to come forward.
- Promotional Material Issues: The FDA criticized ImmunityBio's promotional materials for misleading the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, emphasizing the lack of data supporting such efficacy claims, which poses serious public health risks.
- Investor Alert: Hagens Berman encourages investors to report their losses and warns knowledgeable individuals to consider assisting in the investigation, indicating significant challenges for the company regarding transparency and compliance, which could lead to broader legal and financial repercussions.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, and failure to act may result in lost compensation opportunities.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, leading to investor losses when the truth emerged, potentially impacting the company's reputation and stock performance.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ImmunityBio in the Central District of California on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026, alleging false and misleading statements during this period.
- Allegations of Misrepresentation: The lawsuit claims that CEO Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading statements about ImmunityBio's business and prospects, causing investors to suffer damages when the truth emerged.
- Investor Rights Protection: Affected investors must apply by May 26, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to encourage investors to reach out for assistance.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive experience in protecting investor rights and a commitment to serving clients across federal and state courts.
See More
ImmunityBio's ANKTIVA Therapy Economic Analysis Reveals Significant Cost Savings
- Significant Cost Savings: ImmunityBio's analysis indicates that ANKTIVA plus BCG can save up to $151,438 per cystectomy avoided in a U.S. Medicare population, highlighting the therapy's potential to reduce healthcare expenditures.
- Comparative Efficacy Advantage: The complete response rate for ANKTIVA plus BCG stands at 49.6%, surpassing TAR-200's 45.9%, while also incurring lower treatment and administration costs, showcasing ANKTIVA's competitive edge in treating BCG-unresponsive NMIBC patients.
- Economic Model Support: The findings are derived from a cost-consequence model utilizing data from ImmunityBio's QUILT-3.032 study and TAR-200's SunRISe-1 trial, emphasizing the potential of ANKTIVA plus BCG to deliver durable responses while lowering costs to the healthcare system.
- Optimistic Investor Sentiment: ImmunityBio's stock has surged 291% year-to-date and 192% over the past 12 months, reflecting a positive investor reaction to the economic analysis results and indicating strong market confidence in the company's future growth.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased securities between January 19 and March 24, 2026, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, leading to materially false and misleading statements about the company's business and prospects, which could result in significant losses for investors.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, demonstrating the legal team's commitment to protecting investor rights.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only if they successfully recover funds, highlighting the firm's strong focus on investor interests and accountability.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that executives made false statements during the class period, resulting in investor losses once the true information was revealed, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and secured over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success rather than those acting merely as intermediaries, ensuring they receive the best representation and support in litigation.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Lawsuit Context: The class action lawsuit seeks to represent investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws, with Hagens Berman investigating claims and urging affected investors to come forward.
- Promotional Material Issues: The FDA criticized ImmunityBio's promotional materials for misleading the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, emphasizing the lack of data supporting such efficacy claims, which poses serious public health risks.
- Investor Alert: Hagens Berman encourages investors to report their losses and warns knowledgeable individuals to consider assisting in the investigation, indicating significant challenges for the company regarding transparency and compliance, which could lead to broader legal and financial repercussions.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, and failure to act may result in lost compensation opportunities.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, leading to investor losses when the truth emerged, potentially impacting the company's reputation and stock performance.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ImmunityBio in the Central District of California on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026, alleging false and misleading statements during this period.
- Allegations of Misrepresentation: The lawsuit claims that CEO Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading statements about ImmunityBio's business and prospects, causing investors to suffer damages when the truth emerged.
- Investor Rights Protection: Affected investors must apply by May 26, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to encourage investors to reach out for assistance.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive experience in protecting investor rights and a commitment to serving clients across federal and state courts.
See More
